Allogene Therapeutics

Learn how our experience and differentiated science is enabling us to design and develop a CAR T 2.0 product for autoimmune disease that is scalable and could eliminate or reduce lymphodepletion to meet the unique needs of patients. $ALLO #CART #celltherapy #immunotherapy Uncover the Potential of ALLO-329: Allogene.com/Pipeline

We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: Allogene.com/Pipeline

We look forward to presenting at the 43rd annual J.P. Morgan Healthcare Conference. Join us live or tune in to our webcast on Wednesday, January 15 at 3:00 pm PT to learn more about our potentially practice changing #CART trials and plans to redefine the future of CAR T. https://lnkd.in/gWcN3TBp

As we look ahead to the New Year, we want to take a moment to express our heartfelt gratitude for the dedication, hard work, and passion of our Allogene Team. Your commitment and teamwork have been – and will continue to be – the driving force behind our success. #Teamwork #CART allogene.com

We are deeply saddened by the passing of our founding board member and dear friend, David Bonderman. Our deepest sympathies go out to the Bonderman family and all of those who were fortunate to know him. We will continue to honor his legacy in our work to cure disease. https://lnkd.in/grFM3nt2

ALLO-316, a CD70-targeting chimeric antigen receptor (CAR) T-cell therapy, has demonstrated activity in patients with relapsed or refractory advanced clear cell renal cell carcinoma. https://lnkd.in/dnCm5Tsa

CIRM spoke with John LeGall, MD, the principal investigator of ALLO-316, an allogeneic CAR-T cell therapy targeting CD70—a protein prevalent in clear cell RCC tumors. This groundbreaking therapy, developed by Allogene Therapeutics, received funding support from CIRM. Recently, the FDA designated ALLO-316 an RMAT designation, highlighting its potential to transform the treatment of metastatic renal cell carcinoma (RCC). RCC remains a challenging diagnosis, with limited treatment options and a five-year survival rate of less than 17%. Early findings from the Phase 1 TRAVERSE trial suggest promising results, including encouraging response rates and enhanced anti-tumor activity.

At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver ‘off-the-shelf’ CAR T products that do what autologous CAR T therapies cannot. $ALLO #CART #celltherapy #immunotherapy Explore Innovation at Allogene: Allogene.com/Science

At #ASH24 we presented a trial in progress poster highlighting the aim of our groundbreaking ALPHA3 trial to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: https://lnkd.in/gJJnsf5z